US FDA's Real-Time Oncology Review Times Coming Into Focus

It's been almost a year since then-US Food and Drug Administration commissioner Scott Gottlieb first unveiled the agency's Real-Time Oncology Review (RTOR) pilot last June, and now AbbVie Inc. and Genentech Inc.'s Venclexta (venetoclax tablets) has become the seventh drug to score an approval under the program.

The RTOR pilot is designed to speed the review of certain supplemental oncology indications that appear likely to demonstrate substantial improvement over existing therapy, and it looks like a roughly